InflaRx N.V. IFRX

IFRX Company Overview

InflaRx N.V. is a clinical-stage biopharmaceutical company focused on developing anti-inflammatory therapeutics targeting the complement system, particularly the complement factor C5a and its receptor C5aR. The company operates within the biotechnology and immunology sectors, with research and development activities centered on severe inflammatory and autoimmune diseases. Its lead product candidate, vilobelimab (also known as IFX-1 or Gohibic), is a monoclonal antibody designed to selectively inhibit C5a while preserving the membrane attack complex, a feature the company positions as a differentiated approach within complement-targeted therapies.

The company was founded in Germany and later incorporated in the Netherlands, with operations expanding into the United States through InflaRx Pharmaceuticals, Inc. InflaRx became publicly traded on Nasdaq under the ticker IFRX in 2017. The company gained broader visibility during the COVID-19 pandemic through development efforts involving vilobelimab for critically ill patients with severe COVID-19. Public filings and corporate disclosures indicate that InflaRx continues to prioritize inflammatory indications including hidradenitis suppurativa, pyoderma gangrenosum, and other complement-mediated diseases.